Skip to content

Mindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease

Mindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07402811
Acronym
REMedy
Enrollment
25
Registered
2026-02-11
Start date
2025-12-06
Completion date
2026-05-08
Last updated
2026-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain, Sickle Cell Disease, Sleep Disturbance

Keywords

sleep, mindfulness-based intervention, mobile health, feasibility study, pain management

Brief summary

This study examines the feasibility and acceptability of a mindfulness-based mobile intervention designed to support pain and sleep management among adolescents and young adults with sickle cell disease. Chronic pain and sleep problems are common in this population and can negatively affect daily functioning and quality of life. Participants will use a smartphone-based mindfulness program that includes structured modules and guided mindfulness exercises over an approximately 8-week period. The study aims to evaluate whether the intervention is feasible and acceptable for adolescents and young adults with sickle cell disease.

Interventions

BEHAVIORALMobile bindfulness-based intervention

Participants receive a mindfulness-based mobile intervention designed to support symptom management related to pain and sleep. The intervention is delivered via a smartphone application and includes structured mindfulness content such as guided meditation and brief mindfulness exercises. Participants are asked to engage with the intervention over an approximately 8-week period. The study evaluates feasibility and acceptability.

Sponsors

University of Illinois at Chicago
Lead SponsorOTHER
National Institute of Nursing Research (NINR)
CollaboratorNIH

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
15 Years to 39 Years
Healthy volunteers
No

Inclusion criteria

* Individuals aged 15-39 years * Have been diagnosed with SCD * Are able to speak and understand English * Are able to complete questionnaires with minimal or no assistance from a caregiver * Report pain and/or sleep problems as assessed by the Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) short forms * Have access to the internet on a smartphone, tablet, or computer

Exclusion criteria

* Individuals who have significant cognitive limitations that will impair their ability to use and understand the MBI, as per their health care provider or caregiver * Are currently receiving an MBI or have received more than 4 sessions of any MBI in the 6 months prior to the screening

Design outcomes

Primary

MeasureTime frameDescription
Participant retention rateAt 8 weeks (post-intervention)Percentage of enrolled participants who remain in the study through the 8-week intervention period
Attrition rate and reasons for withdrawalThroughout the 8-week intervention periodPercentage of participants who withdraw from the study and documented reasons for withdrawal
Weekly module completion rateAt 8 weeks (post-intervention)Percentage of assigned weekly modules completed by participants
Acceptability of the Mindfulness-Based InterventionAt 8 weeks (post-intervention)Acceptability of the digital mindfulness-based intervention assessed using a study-specific acceptability questionnaire. The questionnaire measures multiple dimensions including comfort level, effort required to engage, perceived fairness for patients with sickle cell disease, perceived effectiveness for pain and sleep management, clarity of intervention purpose, confidence in the intervention, interference with other priorities, and overall acceptability. The questionnaire uses 5-point rating scales for all items. The questionnaire also includes open-ended questions about device use, suggested improvements, and helpful and unhelpful aspects of the intervention.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORDahee Wi, PhD, RN

University of Illinois at Chicago

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 28, 2026